Immuron Ltd — Board/Management Information 2013

May 27, 2013

==> picture [199 x 43] intentionally omitted <==

ASX Announcement / Media Release

Tuesday 28[th] May 2013

Appointment of New Non-Executive Director – Stephen Anastasiou

Immuron Limited [ASX:IMC] (the Company) is pleased to announce the appointment of Mr Stephen Anastasiou to serve as a Non-Executive Director of the Company.

Mr Anastasiou; B.Sc(Hons), Grad. Dip MKTG, MBA, has over 20 years’ experience in general management, marketing and strategic planning within the healthcare industry.

His breadth of experience incorporates diagnostics, ethical, hospital, dental and OTC products, with companies including the international pharmaceutical company Bristol Myer Squibb.

As a management consultant with KPMG Peat Marwick, Mr. Anastasiou has previously led project teams in a diverse range of market development and strategic planning projects in both the public and private sector. He is also a director and shareholder of a number of unlisted private companies, covering a variety of industry sectors that include healthcare and funds management.

Mr Anastasiou’s companies have participated in several corporate transactions involving business units and brands of multinational and Australian companies.

The Board wishes to formally welcome Mr Anastasiou to the Company, and further recognise that his extensive healthcare market experience will further strengthen the Board’s capabilities.

For and on behalf of the Board,

Kind Regards;

==> picture [116 x 38] intentionally omitted <==

Roger Aston Non-Executive Chairman Immuron Limited

About Immuron

Immuron is a biopharmaceutical company focused on oral immunotherapy treatments using dairy-derived antibody products for humans. Immuron is uniquely positioned with a versatile technology platform capable of generating a wide range of products with a high safety profile. This high safety profile makes it possible to complete pre-clinical studies relatively quickly and increases the prospect that the clinical development of Immuron’s products will be expedited. Immuron’s current products and product candidates target infectious diseases of the gastrointestinal tract, chronic diseases such as fatty liver/NASH, and Clostridium difficile. Immuron has one product on the market, Travelan, for preventing travellers’ diarrhoea. Immuron’s main scientific alliances are with Hadassah Medical Centre (Israel), the University of Melbourne and Monash University (Australia).

Level 1 18 Kavanagh Street www.immuron.com Phone: + 61 (0)3 8648 4530 Southbank, Vic 3006 Facsimile: + 61 (0)3 9686 9460 ABN: 80 063 114 045